Transcutaneous immunization with influenza vaccines

Current Topics in Microbiology and Immunology

Volumn 333, Issue 1, 2009, Pages 347-368

  Skountzou, Ioanna ^a   Kang, Sang Moo ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DNA VACCINE; ENTEROTOXIN; HERPES SIMPLEX VACCINE; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; OLEIC ACID; PEPTIDE VACCINE; RETINOIC ACID; VIRUS ANTIGEN; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; CELL POPULATION; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG ERUPTION; DRUG MECHANISM; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA VACCINATION; INNATE IMMUNITY; LANGERHANS CELL; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SKIN ALLERGY; SKIN PENETRATION; SKIN STRUCTURE;

EID: 77953211852     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-92165-3_17     Document Type: Review

References (102)

1. Anjuere F, George-Chandy A, Audant F, Rousseau D, Holmgren J, Czerkinsky C (2003) Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses. J Immunol 170:1586-1592
2. Atkinson WL, Pickering LK, Schwartz B, Weniger BG, Iskander JK, Watson JC (2002) General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep 51:1-35
3. Baca-Estrada ME, Foldvari M, Ewen C, Badea I, Babiuk LA (2000) Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipid-based biphasic delivery system. Vaccine 18:1847-1854
4. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-252
5. Barker CJ, Bowler K (1991) Lipid composition of the membranes from cells of two rat tumors and its relationship to tumor thermosensitivity. Radiat Res 125:48-55
6. Beignon AS, Briand JP, Muller S, Partidos CD (2002) Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells. Immunology 105:204-212
7. Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA (2004) Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 113:998-1007
8. Berking C, Takemoto R, Binder RL, Hartman SM, Ruiter DJ, Gallagher PM, Lessin SR, Herlyn M (2002) Photocarcinogenesis in human adult skin grafts. Carcinogenesis 23:181-187
9. Berry LJ, Hickey DK, Skelding KA, Bao S, Rendina AM, Hansbro PM, Gockel CM, Beagley KW (2004) Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun 72:1019-1028
10. Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ, Kwak LW (2002) Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298:1025-1029
11. Bos JD, Meinardi MM (2000) The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 9:165-169
12. Caux C, Ait-Yahia S, Chemin K, De Bouteiller O, Dieu-Nosjean MC, Homey B, Massacrier C, Vanbervliet B, Zlotnik A, Vicari A (2000) Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol 22:345-369
13. Chen D, Endres RL, Erickson CA, Weis KF, McGregor MW, Kawaoka Y, Payne LG (2000) Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat Med 6:1187-1190
14. Chen D, Erickson CA, Endres RL, Periwal SB, Chu Q, Shu C, Maa YF, Payne LG (2001a) Adjuvantation of epidermal powder immunization. Vaccine 19:2908-2917
15. Chen D, Periwal SB, Larrivee K, Zuleger C, Erickson CA, Endres RL, Payne LG (2001b) Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J Virol 75:7956-7965
16. Chen D, Weis KF, Chu Q, Erickson C, Endres R, Lively CR, Osorio J, Payne LG (2001c) Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses. J Virol 75:11630-11640
17. Chen D, Endres R, Maa YF, Kensil CR, Whitaker-Dowling P, Trichel A, Youngner JS, Payne LG (2003) Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine 21:2830-2836
18. Combadiere B, Mahe B (2008) Particle-based vaccines for transcutaneous vaccination. Comp Immunol Microbiol Infect Dis 31(2-3):293-315
19. Compans RW, Klenk HD, Caliguiri LA, Choppin PW (1970) Influenza virus proteins. Analysis I of polypeptides of the virion and identification of spike glycoproteins. Virology 42:880-889
20. Cumberbatch M, Dearman RJ, Kimber I (1997) Langerhans cells require signals from both tumour necrosis factor-alpha and interleukin-1 beta for migration. Immunology 92:388-395
21. Das P (2004) Revolutionary vaccine technology breaks the cold chain. Lancet Infect Dis 4:719
22. Debenedictis C, Joubeh S, Zhang G, Barria M, Ghohestani RF (2001) Immune functions of the skin. Clin Dermatol 19:573-585
23. Dell K, Koesters R, Gissmann L (2006) Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors. Int J Cancer 118:364-372
24. Dieu-Nosjean MC, Massacrier C, Homey B, Vanbervliet B, Pin JJ, Vicari A, Lebecque S, Dezutter-Dambuyant C, Schmitt D, Zlotnik A, Caux C (2000) Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J Exp Med 192:705-718
25. Ekwueme DU, Weniger BG, Chen RT (2002) Model-based estimates of risks of disease transmission and economic costs of seven injection devices in sub-Saharan Africa. Bull World Health Organ 80:859-870
26. El-Ghorr AA, Williams RM, Heap C, Norval M (2000) Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice. FEMS Immunol Med Microbiol 29:255-261
27. Elias PM, Feingold KR (1992) Lipids and the epidermal water barrier: metabolism, regulation, and pathophysiology. Semin Dermatol 11:176-182
28. Enioutina E Y, Visic D, Daynes RA (2000) The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine 18:2753-2767
29. Freytag LC, Clements JD (1999) Bacterial toxins as mucosal adjuvants. Curr Top Microbiol Immunol 236:215-236
30. Giudice EL, Campbell JD (2006) Needle-free vaccine delivery. Adv Drug Deliv Rev 58:68-89
31. Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, Alving CR (1998) Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol 161:3211-3214
32. Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR (2000) Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 6:1403-1406
33. Glenn GM, Kenney RT, Ellingsworth LR, Frech SA, Hammond SA, Zoeteweij JP (2003a) Transcutaneous immunization and immunostimulant strategies: capitalizing on the immuno-competence of the skin. Expert Rev Vaccines 2:253-267
34. Glenn GM, Kenney RT, Hammond SA, Ellingsworth LR (2003b) Transcutaneous immunization and immunostimulant strategies. Immunol Allergy Clin North Am 23:787-813
35. Glenn GM, Villar CP, Flyer DC, Bourgeois AL, McKenzie R, Lavker RM, Frech SA (2007) Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect Immun 75:2163-2170
36. Godefroy S, Goestch L, Plotnicky H-Gilquin, Nguyen TN, Schmitt D, Staquet MJ, Corvaia N (2003) Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against respiratory syncytial virus (RSV). Vaccine 21:1665-1671
37. Guebre-Xabier M, Hammond SA, Epperson DE, Yu J, Ellingsworth L, Glenn GM (2003) Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J Virol 77:5218-5225
38. Guerena-Burgueno F, Hall ER, Taylor DN, Cassels FJ, Scott DA, Wolf MK, Roberts ZJ, Nesterova G V, Alving CR, Glenn GM (2002) Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 70:1874-1880
39. Itano AA, McSorley SJ, Reinhardt RL, Ehst BD, Ingulli E, Rudensky AY, Jenkins MK (2003) Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 19:47-57
40. Johnston D, Bystryn JC (2006) Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine 24:1958-1965
41. Kahlon R, Hu Y, Orteu CH, Kifayet A, Trudeau JD, Tan R, Dutz JP (2003) Optimization of epicutaneous immunization for the induction of CTL. Vaccine 21:2890-2899
42. Kane M, Lasher H (2002) The case for childhood immunization (Occasional Paper 5). Children's Vaccine Program at PATH, Seattle (see http://www.path.org/ vaccineresources/files/CVP-Occ-Paper5.pdf)
43. Kermode M (2004) Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot Int 19:95-103
44. Khavari PA (2006) Modelling cancer in human skin tissue. Nat Rev Cancer 6:270-280
45. Kim SS, Chen YM, O'Leary E, Witzgall R, Vidal M, Bonventre JV (1996) A novel member of the RING finger family, KRIP-1, associates with the KRAB-A transcriptional repressor domain of zinc finger proteins. Proc Natl Acad Sci USA 93:15299-15304
46. Kligman AM, Dogadkina D, Lavker RM (1993) Effects of topical tretinoin on non-sun-exposed protected skin of the elderly. J Am Acad Dermatol 29:25-33
47. Klimuk SK, Najar HM, Semple SC, Aslanian S, Dutz JP (2004) Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL. J Invest Dermatol 122:1042-1049
48. Klinman DM, Currie D, Gursel I, Verthelyi D (2004) Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 199:201-216
49. Kondo H, Ichikawa Y, Imokawa G (1998) Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response. Eur J Immunol 28:769-779
50. Kupper T, Harasani X, Trakanvanich V, Pfitzer P (1996) Cytomorphologic findings in fine needle aspiration specimens of eosinophilic renal cell carcinoma. Gen Diagn Pathol 141:249-253
51. Larregina AT, Morelli AE, Spencer LA, Logar AJ, Watkins SC, Thomson AW, Falo LD Jr, (2001) Dermal-resident CD14+ cells differentiate into Langerhans cells. Nat Immunol 2:1151-1158
52. Lenz A, Heine M, Schuler G, Romani N (1993) Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization. J Clin Invest 92:2587-2596
53. Matyas GR, Friedlander AM, Glenn GM, Little S, Yu J, Alving CR (2004) Needle-free skin patch vaccination method for anthrax. Infect Immun 72:1181-1183
54. McGrew R, McGrew M (1985) Encyclopedia of medical history. McGraw Hill, New York
55. McKenzie R, Bourgeois AL, Engstrom F, Hall E, Chang HS, Gomes JG, Kyle JL, Cassels F, Turner AK, Randall R, Darsley M, Lee C, Bedford P, Shimko J, Sack DA (2006) Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults. Infect Immun 74:994-1000
56. Merad M, Manz MG, Karsunky H, Wagers A, Peters W, Charo I, Weissman IL, Cyster JG, Engleman EG (2002) Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 3:1135-1141
57. Miller MA, Pisani E (1999) The cost of unsafe injections. Bull World Health Organ 77:808-811
58. Mitragotri S (2005) Immunization without needles. Nat Rev Immunol 5:905-916
59. Mohty M, Morbelli S, Isnardon D, Sainty D, Arnoulet C, Gaugler B, Olive D (2003) All-trans retinoic acid skews monocyte differentiation into interleukin-12-secreting dendritic-like cells. Br J Haematol 122(5):829-836
60. Mkrtichyan M, Ghochikyan A, Movsesyan N, Karapetyan A, Begoyan G, Yu J, Glenn GM, Ross TM, Agadjanyan MG, Cribbs DH (2008) Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization. DNA Cell Biol 27(1):19-24
61. Morel PA, Falkner D, Plowey J, Larregina AT, Falo LD (2004) DNA immunisation: altering the cellular localisation of expressed protein and the immunisation route allows manipulation of the immune response. Vaccine 22:447-456
62. Mosmann TR (1994) Properties and functions of interleukin-10. Adv Immunol 56:1-26
63. Moylett EH, Hanson IC (2004) Mechanistic actions of the risks and adverse events associated with vaccine administration. J Allergy Clin Immunol 114:1010-1020; quiz 1021
64. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350:896-903
65. Nickoloff BJ, Naidu Y (1994) Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol 30:535-546
66. Nickoloff BJ, Mitra RS, Green J, Zheng XG, Shimizu Y, Thompson C, Turka LA (1993) Accessory cell function of keratinocytes for superantigens. Dependence on lymphocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. J Immunol 150:2148-2159
67. Norbury CC, Malide D, Gibbs JS, Bennink JR, Yewdell JW (2002) Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo. Nat Immunol 3:265-271
68. Norval M (2008) The photobiology of human skin. In: Photobiology: the science of life and light, 2nd edn. Springer, New York, pp 553-576
69. Partidos CD (2003) Delivering vaccines into the skin without needles and syringes. Expert Rev Vaccines 2:753-761
70. Partidos CD, Muller S (2005) Decision-making at the surface of the intact or barrier disrupted skin: potential applications for vaccination or therapy. Cell Mol Life Sci 62:1418-1424
71. Price AA, Cumberbatch M, Kimber I, Ager A (1997) Alpha 6 integrins are required for Langerhans cell migration from the epidermis. J Exp Med 186:1725-1735
72. Romani N, Tschachler E, Schuler G, Aberer W, Ceredig R, Elbe A, Wolff K, Fritsch PO, Stingl G (1985) Morphological and phenotypical characterization of bone marrow-derived dendritic Thy-1-positive epidermal cells of the mouse. J Invest Dermatol 85:91s-95s
73. Roth Y, Chapnik JS, Cole P (2003) Feasibility of aerosol vaccination in humans. Ann Otol Rhinol Laryngol 112:264-270
74. Ruffini PA, Biragyn A, Kwak LW (2002) Recent advances in multiple myeloma immunotherapy. Biomed Pharmacother 56:129-132
75. Schaefer H, Lademann J (2001) The role of follicular penetration. A differential view. Skin Pharmacol Appl Skin Physiol 14(suppl 1):23-27
76. Scharton-Kersten T, Yu J, Vassell R, O'Hagan D, Alving CR, Glenn GM (2000) Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun 68:5306-5313
77. Schon MP, Orfanos CE (1995) Transformation of human keratinocytes is characterized by quantitative and qualitative alterations of the T-16 antigen (Trop-2, MOv-16). Int J Cancer 60:88-92
78. Seo N, Tokura Y, Nishijima T, Hashizume H, Furukawa F, Takigawa M (2000) Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc Natl Acad Sci \USA 97:371-376
79. Skountzou I, Quan FS, Jacob J, Compans RW, Kang SM (2006) Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 24:6110-6119
80. Sozzani S, Allavena P, D'Amico G, Luini W, Bianchi G, Kataura M, Imai T, Yoshie O, Bonecchi R, Mantovani A (1998a) Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J Immunol 161:1083-1086
81. Sozzani S, Bonecchi R, D'Amico G, Luini W, Bernasconi S, Allavena P, Mantovani A (1998b) Old and new chemokines. Pharmacological regulation of chemokine production and receptor expression: mini-review. J Chemother 10:142-145
82. Sozzani S, Allavena P, Vecchi A, Mantovani A (2000) Chemokines and dendritic cell traffic. J Clin Immunol 20:151-160
83. Steinhoff M, Brzoska T, Luger TA (2001) Keratinocytes in epidermal immune responses. Curr Opin Allergy Clin Immunol 1:469-476
84. Stingl G, Steiner G (1989) Immunological host defense of the skin. Curr Probl Dermatol 18:22-30
85. Streilein JW (1983) Skin-associated lymphoid tissues (SALT): origins and functions. J Invest Dermatol 80(suppl):12s-16s
86. Tezel A, Paliwal S, Shen Z, Mitragotri S (2005) Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine 23:3800-3807
87. Tierney R, Beignon AS, Rappuoli R, Muller S, Sesardic D, Partidos CD (2003) Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. J Infect Dis 188:753-758
88. Touitou E, Godin B, Karl Y, Bujanover S, Becker Y (2002) Oleic acid, a skin penetration enhancer, affects Langerhans cells and corneocytes. J Control Release 80:1-7
89. Uchi H, Terao H, Koga T, Furue M (2000) Cytokines and chemokines in the epidermis. J Dermatol Sci 24(suppl 1):S29-S38
90. Valladeau J, Ravel O, Dezutter-Dambuyant C, Moore K, Kleijmeer M, Liu Y, Duvert-Frances V, Vincent C, Schmitt D, Davoust J, Caux C, Lebecque S, Saeland S (2000) Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 12:71-81
91. Varani J, Zeigler M, Dame MK, Kang S, Fisher GJ, Voorhees JJ, Stoll SW, Elder JT (2001b) Heparin-binding epidermal-growth-factor-like growth factor activation of keratinocyte ErbB receptors mediates epidermal hyperplasia, a prominent side-effect of retinoid therapy. J Invest Dermatol 117:1335-1341
92. Vogt A, Mandt N, Lademann J, Schaefer H, Blume-Peytavi U (2005) Follicular targeting\-a promising tool in selective dermatotherapy. J Investig Dermatol Symp Proc 10:252-255
93. Vogt A, Combadiere B, Hadam S, Stieler KM, Lademann J, Schaefer H, Autran B, Sterry W, Blume-Peytavi U (2006) 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Invest Dermatol 126:1316-1322
94. Watford WT, Moriguchi M, Morinobu A, O'Shea JJ (2003) The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 14:361-368
95. Weir E, Hatch K (2004) Preventing cold chain failure: vaccine storage and handling. CMAJ 171:1050
96. Williams IR, Kupper TS (1996) Immunity at the surface: homeostatic mechanisms of the skin immune system. Life Sci 58:1485-1507
97. Wolff K, Honigsmann H (1971) Permeability of the epidermis and the phagocytic activity of keratinocytes. Ultrastructural studies with thorotrast as a marker. J Ultrastruct Res 36:176-190
98. Wood LC, Jackson SM, Elias PM, Grunfeld C, Feingold KR (1992) Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. J Clin Invest 90:482-487
99. WHO (2004) Safety of infections: global facts and figures (Factsheet 275). World Health Organization, Geneva (see http://www.path.org/ vaccineresources/details.php?i=275)
100. WHO (2006) Injection safety (Factsheet 231). World Health Organization, Geneva (http://whqlibdoc. who.int/fact-sheet/2006/FS-231.pdf)
101. Yu J, Cassels F, Scharton-Kersten T, Hammond SA, Hartman A, Angov E, Corthesy B, Alving C, Glenn G (2002) Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect Immun 70:1056-1068
102. Zhao YL, Murthy SN, Manjili MH, Guan LJ, Sen A, Hui SW (2006) Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. Vaccine 24:1282-1290